FY2020 Earnings Forecast for Retrophin Inc Issued By Jefferies Financial Group (NASDAQ:RTRX)

Retrophin Inc (NASDAQ:RTRX) – Equities research analysts at Jefferies Financial Group decreased their FY2020 EPS estimates for Retrophin in a research note issued on Wednesday, July 31st. Jefferies Financial Group analyst M. Raycroft now anticipates that the biopharmaceutical company will earn ($3.41) per share for the year, down from their prior forecast of ($3.32). Jefferies Financial Group also issued estimates for Retrophin’s FY2021 earnings at ($3.01) EPS, FY2022 earnings at ($1.83) EPS and FY2023 earnings at $0.75 EPS.

Retrophin (NASDAQ:RTRX) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.65) by ($0.27). The business had revenue of $44.71 million for the quarter, compared to analyst estimates of $43.01 million. Retrophin had a negative return on equity of 41.38% and a negative net margin of 75.75%. The company’s revenue was up 8.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.25) EPS.

Several other brokerages have also weighed in on RTRX. Canaccord Genuity upped their price objective on Retrophin from $37.00 to $41.00 and gave the company a “buy” rating in a report on Monday, July 1st. Barclays initiated coverage on Retrophin in a report on Monday, April 22nd. They issued an “overweight” rating and a $36.00 price objective for the company. William Blair restated a “buy” rating on shares of Retrophin in a report on Friday, July 5th. Zacks Investment Research upgraded Retrophin from a “sell” rating to a “hold” rating in a report on Wednesday, July 10th. Finally, BidaskClub lowered Retrophin from a “hold” rating to a “sell” rating in a report on Thursday, July 25th. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $44.50.

Shares of Retrophin stock opened at $19.24 on Monday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.52 and a current ratio of 4.57. The firm has a market capitalization of $788.54 million, a price-to-earnings ratio of -7.57 and a beta of 0.90. The company has a fifty day moving average price of $20.41. Retrophin has a fifty-two week low of $17.53 and a fifty-two week high of $33.00.

Several hedge funds and other institutional investors have recently made changes to their positions in RTRX. SG Americas Securities LLC purchased a new stake in shares of Retrophin during the first quarter valued at $143,000. Campbell & CO Investment Adviser LLC acquired a new position in Retrophin during the first quarter valued at $217,000. Metropolitan Life Insurance Co. NY raised its position in Retrophin by 318.5% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 13,785 shares of the biopharmaceutical company’s stock valued at $312,000 after buying an additional 10,491 shares during the period. Mercer Global Advisors Inc. ADV acquired a new position in Retrophin during the first quarter valued at $327,000. Finally, Legal & General Group Plc raised its position in Retrophin by 17.2% during the fourth quarter. Legal & General Group Plc now owns 15,866 shares of the biopharmaceutical company’s stock valued at $360,000 after buying an additional 2,325 shares during the period.

In other news, COO Neil F. Mcfarlane sold 1,968 shares of the company’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $18.25, for a total transaction of $35,916.00. Following the completion of the sale, the chief operating officer now directly owns 27,972 shares of the company’s stock, valued at $510,489. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Laura Clague sold 2,500 shares of the company’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $18.25, for a total value of $45,625.00. Following the sale, the chief financial officer now directly owns 14,750 shares of the company’s stock, valued at $269,187.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 13,319 shares of company stock valued at $244,378. 4.32% of the stock is currently owned by company insiders.

Retrophin Company Profile

Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

Recommended Story: Bollinger Bands

Earnings History and Estimates for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.